Red Wine Mist? Resveratrol
Shows Unique Anti-Inflammatory Effects In Human Lung; COPD, Asthma Potential
Seen
The current research aimed to confirm and quantify the
effect of resveratrol and quercetin, a related plant-derived polyphenolic
compound that often mimics its diverse activities, and to further study the
molecular mechanisms involved.
While resveratrol “exhibited anti-inflammatory activity
in all the systems we examined,” the researchers said, “it appeared to be
more effective, although less potent, than glucocorticoids. Resveratrol also
inhibited inflammatory mediator release from human airway epithelial cells (HAEC),
inhibited iNOS and COX-2 (cyclooxygenase) gene transcription, together with
IL-8 and GM-CSF expression in HAEC. The inhibition of iNOS (inducible nitric
oxide synthase) expression and activity in primary HAEC is significant,
because steroids are ineffective in this system,” the paper states.
IL-8 (interleukin-8) and GM-CSF (granulocyte-macrophage
colony-stimulating factor) are important in the inflammation development,
they noted, because IL-8 plays a major role in the recruitment of
inflammatory leukocytes, particularly neutrophils, and GM-CSF is a cell
survivor factor, thus prolonging the resident time of inflammatory cells.
“The differential inhibitory effects of resveratrol on IL-8 and GM-CSF
release (shown in this study) further suggest that resveratrol is not simply
acting as a general inhibitor of inflammatory mediator release but exhibits
some selectivity.”
Next steps: further narrow mechanisms of broad
anti-inflammatory
Donnelly et al. conclude that resveratrol and quercetin
“can act as novel anti-inflammatory agents. Their mechanism of action is not
via the estrogen or glucocorticoid receptor; thus these agents might be
beneficial in inflammatory diseases where glucocorticosteroids have proved
to be ineffective, such as COPD, steroid-resistant asthma, and arthritis.
These compounds may provide candidate molecules for the development of novel
anti-inflammatory therapies.”
The current study “excluded a lot” of potential
mechanisms of action, Donnelly said, but we
“still don’t know what its target receptor is as it binds like a protein,
but acts like an estrogen,” which it’s not. “The good thing is that it does
stop inflammation” across a broad range of systems, she added.
Source and funding: The article,
“Anti-inflammatory effects of resveratrol in lung epithelial cells:
molecular mechanisms,” appears in the October issue of American Journal
of Physiology-Lung Cellular and Molecular Physiology, published by the
American Physiological Society.
In addition to Donnelly, other members of the research
team, all from the Department of Thoracic Medicine, National Heart & Lung
Institute, Imperial College London, England, are: Robert Newton, Gina E.
Kennedy, Peter S. Fenwick, Rachel H.F. Leung, Kazuhiro Ito, Richard E.K.
Russell and Peter J. Barnes.
Research was funded by grants from Pharmascience Inc.,
Pharmacia (part of Pfizer Inc.), the British Lung Foundation and the
National Asthma Campaign (UK).
Editor’s note: A copy of the research paper by
Donnelly et al. is available to the media. Members of the media are
encouraged to obtain an electronic version and to interview members of the
research team. To do so, please contact Donna Krupa at APS (301) 634-7209,
cell (703) 967-2751 or
dkrupa@the-aps.org.
* * *
The
American Physiological Society was founded in 1887 to foster basic and
applied bioscience. The Bethesda, Maryland-based society has more than
10,000 members and publishes 14 peer-reviewed journals containing almost
4,000 articles annually.
APS
provides a wide range of research, educational and career support and
programming to further the contributions of physiology to understanding the
mechanisms of diseased and healthy states. In May, APS received
the Presidential Award for Excellence in Science,
Mathematics and Engineering Mentoring (PAESMEM).
# # #